INTRODUCTION: @entity1192 ( @entity1192 ) is the key molecule of a strong pro-inflammatory pathway in the innate immune system. The @entity1192 family harbors components with pro- and anti-inflammatory effects essential for the regulation of the @entity32 process. Auto-inflammatory diseases and systemic onset @entity4932 ( @entity4932 ) are examples of chronic inflammatory diseases that are @entity1192 dependent. @entity1192 blockade has proven to be very effective and has greatly improved the outcome of these disorders. Areas covered: This review describes the components of the @entity1192 family and the available @entity1192 blocking agents for clinical practice. Among them, canakinumab was more recently introduced. Based on the published clinical trials one can conclude that the clinical efficacy in auto-inflammatory diseases is at least as good as other @entity1192 blocking agents. The safety data are limited to those registration studies (Phase 2 and 3). In short term the adverse events described are not very different from the other @entity1192 blockers. Expert opinion: Longer term use in larger numbers of @entity1 and adequate data collection using large-scale registries are necessary to provide us with a well-balanced overview of safety issues of canakinumab. Registration studies and open label extension studies show an acceptable safety profile so far.

A safety evaluation of canakinumab for the treatment of systemic onset XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1192 :: ('3552', 'Gene') :: ['IL-1', 'Interleukin-1'] @entity4932 :: ('MESH:D001171', 'Disease') :: ['JIA', 'juvenile idiopathic arthritis']
@entity4932 :: (MESH:D001171,Disease) :: ['juvenile idiopathic arthritis']
